Evofem Biosciences Announces Closing of Public Offering of Common Stock
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced the closing of its underwritten public offering of 17,142,857 shares of common stock at $1.75 per share, generating gross proceeds of $30 million. The proceeds will fund commercialization activities related to Phexxi®, a contraceptive vaginal gel, ongoing clinical trials for EVO100, and other corporate purposes. The offering was conducted under Evofem's existing shelf registration statement. Morgan Stanley and Stifel acted as joint book-running managers for the offering.
- Gross proceeds of $30 million to fund commercialization and clinical trials.
- Continued commercialization of Phexxi® through direct-to-consumer advertising.
- Ongoing EVOGUARD Phase 3 clinical trial for EVO100.
- Dilution risk due to the public offering of shares.
SAN DIEGO, March 29, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 17,142,857 shares of its common stock at
Morgan Stanley and Stifel acted as joint book-running managers for the offering.
Evofem intends to use the net proceeds from the offering for the continuation of full commercialization activities related to Phexxi® (lactic acid, citric acid and potassium bitartrate) contraceptive vaginal gel in the United States, including continued direct-to-consumer advertising activities across television, streaming and digital channels, the continuation of its ongoing EVOGUARD Phase 3 clinical trial evaluating EVO100 for the prevention of certain sexually transmitted infections and related development activities, and general corporate purposes and other capital expenditures.
The offering was made only by means of a written prospectus and related prospectus supplement forming part of Evofem's shelf registration statement on Form S-3 (File No. 333-253881) that was previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on March 11, 2021. The final prospectus supplement and accompanying prospectus are available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, Phexxi® contraceptive vaginal gel, in the United States in September 2020. The Company's lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD.'
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to the anticipated use of proceeds from the offering. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business, are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 4, 2021. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.
Investor Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
###
View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-announces-closing-of-public-offering-of-common-stock-301257792.html
SOURCE Evofem Biosciences, Inc.
FAQ
What is the size of Evofem's recent public offering?
What will Evofem do with the proceeds from the public offering?
Who managed Evofem's public offering?
When was the public offering announced?
Is the public offering expected to impact EVFM shareholders?
